Main Article Content
Cranial neuropathy, drug-induced ocular adverse event, neurotrophic keratopathy, rosuvastatin, trigeminal neuropathy
Background and objective:
To report a case of bilateral neurotrophic keratopathy associated with rosuvastatin therapy that dramatically improved following drug discontinuation.
Materials and Methods:
Chart review of the patient’s medical record was performed, and clinical images were analyzed before and after drug discontinuation.
The patient presented with bilateral stage 2 neurotrophic keratopathy with impaired corneal sensation and resistance to conservative ulcer treatment. She had recently started rosuvastatin therapy for hyperlipidemia. Following discontinuation of rosuvastatin therapy, there was dramatic bilateral improvement in corneal sensation, size of the corneal ulcers, and visual acuity.
Rosuvastatin may result in reversible trigeminal nerve impairment and neurotrophic keratopathy.
2. Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003; 17:989–995.
3. Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: A case-control study. Neurology 2002; 58;1333-37.
4. Shi XQ, Lim TKY, Lee S, et al. Statins alleviate experimental nerve injury-induced neuropathic pain. Pain 2011; 152;1033-43.
5. Negevesky GJ, Kolsky MP, Laureno R, Yau TH. Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia. Arch Ophthalmol 2000; 118:427–8.